In a report released today, Justin Walsh from JonesTrading maintained a Buy rating on Actinium Pharmaceuticals (ATNM - Research Report), with a price target of $24.00. The company's shares opened today at $14.47.According to TipRanks, Walsh is an analyst with an average return of -31.4% and a 21.31% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, POINT Biopharma Global, and Plus Therapeutics.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Actinium Pharmaceuticals with a $30.00 average price target, a 107.33% upside from current levels. In a report released today, H.C.
https://www.tipranks.com/news/blurbs/jonestrading-remains-a-buy-on-actinium-pharmaceuticals-atnm?utm_source=advfn.com&utm_medium=referral